Altimmune, Inc.（ALT）の財務ALTAltimmune, Inc.

Evaluating the bottom line, Altimmune, Inc. maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -28.87%, provide a clear picture of how effectively ALT converts its operational activities into shareholder value.

In the context of the broader market, ALT competes directly with industry leaders such as PRTA and CBIO. With a market capitalization of $422.10M, it holds a significant position in the sector. When comparing efficiency, ALT's gross margin of N/A stands against PRTA's 100.00% and CBIO's 100.00%. Such benchmarking helps identify whether Altimmune, Inc. is trading at a premium or discount relative to its financial performance.

Altimmune has shown a gross margin of 100% in the last reported quarters, but it has consistently reported negative net income, with a net income of -22,563,000 USD for Q1 2026. The forward P/E ratio is 8.18, suggesting potential for future earnings, but current financial health is weak.